Biomarin Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript
Good morning, everyone. Welcome. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan, and we're delighted to be continuing the conference with BioMarin this morning. So good news, we're not going to switch rooms for Q&A today. There's going to be mic runners. If you have a question after the presentation, you can raise your hand, and someone will bring you a mic. You can also submit your questions electronically, and I can ask them.
So without further ado, let me pass it over to the company's CEO, JJ Bienaime.
Thank you, Jess. Good morning, everybody. It's a pleasure to be back here in person after this COVID hiatus. As usual, this presentation will contain forward-looking statements. Please refer to our 10-K and 10-Q filings. So again, it's good to be back.
As you know, BioMarin is really anchored in science. And I would say all the genetic products
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
